bi 135585
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2010 (NCT01146886)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
HSD11B1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 6-(2-hydroxy-2-methylpropyl)-3-(1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one
- bi 135585
- bi 135585
- bi 135585
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01652742 | Phase 1 | Jul 1, 2012 | Boehringer Ingelheim |
| NCT01282970 | Phase 1 | Feb 1, 2011 | Boehringer Ingelheim |
| NCT01291732 | Phase 1 | Feb 1, 2011 | Boehringer Ingelheim |
| NCT01286571 | Phase 1 | Jan 1, 2011 | Boehringer Ingelheim |
| NCT01146886 | Phase 1 | Jun 1, 2010 | Boehringer Ingelheim |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 5 | 5 | 1 | 2010 |
1 organizations
Page 1 / 1